

DAFTAR PUSTAKA

- Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, N., M., Marin, S., Alhava, E., *et al.* 1992. Lymphocyte infiltrating as a prognostic variable in female breast cancer. *European Journal of Cancer*, 28A(4-5), p.859.
- Abbas, A.K., Lichman, A.H., & Pillai, S., 2012, Basic Immunology, 4th edition., Elsevier, WB Saunders Co., Saunders Company. *American Society of clinical oncology*. 0732-183X/14/3227w-2959w/\$20.00
- Adam, S., Gray, R.J., Demaria, S., *et al.* 2014. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199.
- Alexe, G., Dalgim, G., S., Scandfeld, D., Tamayo, P., Mesirov, J.P., Delisi, C., *et al.* 2007. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancer correlated with lower recurrence rates. *Cancer Research*, 67 (22), pp. 10669 – 10676.
- Bauer, C.K., Johnson, R., Litton, J., Phillips, M., Bleyer, A., 2009. Breast Cancer before age 40 years. *Semin Oncol* Jun;36(3):237-249.
- Blows, F.M., Driver, K.E., Schmidt, M.K., Broek, A., vanleeuwen, F.E., *et al.* 2010. Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies. *PLoS Med* 7(5): e1000279. doi:10.1371/journal.pmed.1000279.
- Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., *et al.*, 2010. Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy. *Journal Of Clinical Oncology*. VOLUME 28 NUMBER 3 JANUARY 20 2010.
- Carey, K.A., Perou, C.M., Livasy, C.A., *et al.* 2006. Race, Breast Cancer Subtype, and Survival in The California Breast Cancer Study. *JAMA* ;295(21):2492-2502.
- Carey, K.A., Zagar, T.M., *et al.* 2013. The management of Early- Stage and Metastatic Triple-Negative Breast Cancer: A review. *Hematol Oncol Clin N Am*;27:737-749.

- Cheang,M., Chia,S.K., Tu,D.,*et al.* 2009. Anthracyclin in Basal Breast Cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF.J clin oncol;27:519.
- Chlebowski, R.T., Chen, Z., Anderson, G.L., Rohan, T., Aragaki, A., Lane, D., *et al.*, 2005. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J. Natl. Cancer Inst. 97, 439–448.
- Cholleoni,M., Cole,FB.,Vialle,G., *et al.*2010. Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, NodeNegative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer.*Journal of Oncology*. 28:2966-2973.
- Cianfrocca M, Goldstein L. 2014. Prognostic and predictive factors in early – stage breast cancer. The Oncologist, 9;606-616.
- Copson *et al.*, 2018. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.vol9.
- Dahlan M.S. 2010. *Besar Sampel dan Cara Pengambilan Sampel*. Salemba Medika : Jakarta.
- Denkert, C., A., Leffers, N., Boezen, H., M., Ten-Hoor, K., A.,van der zee, A., G., Hollema, H., *et al.* 2009. Presence of Tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. *Gynecology Oncology*, 114 (1), p.105.
- Dent, R., Trudeau, M., Pritchard, K.I., Hanna, W.M., Kahn, H.K., *et al.*, 2007. Triple-Negative Breast cancer: Clinical Features and Pattern of Recurrence *Clin Cancer Res* 13(15).
- Foulkes, W.D., Reis-Filho, J.S., Narod, S.A., 2010. Tumor size and survival in breast cancer--a reappraisal. Nat. Rev. Clin. Oncol. 7, 348–353.
- Gao, G., wang , Z., Qu, X., *et al.* 2020. Prognostic value of tumor- infiltrating lymphocytes in patients with triple-negative breast cancer : a systemic review and meta-analysis. *BMC cancer* .20:179.
- García-tejido1, G., Cabal, M., L., Fernández, I., P., Pérez, Y., F., 2016. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. Clinica Medica insights: *OnCOLOGY*:10(s1).
- Gonçalves, H., Guerra, M.R., Duarte Cintra, J.R., Fayer, V.A., Brum, I.V., Bustamante Teixeira, M.T., 2018. Survival Study of Triple-Negative and

Non–Triple-Negative Breast Cancer in a Brazilian Cohort. Clin. Med. Insights Oncol. 12, 117955491879056. <https://doi.org/10.1177/1179554918790563>.

Gu-Trantien, C., Loi, S., Garaud, S., Equeter, C., Libin, M., de Wind, A., *et al.* 2013. CD4+ follicular helper T cell infiltration predicts breast cancer survival. *The journal of Clinical Investigatuon*,123(7),pp.1-20.

Hammon ME, Hayes DF, Dowsett M, *et al.* 2010. American Society of Clinical oncology/College of American Pathologist Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesteron Receptor in Breast Cancer J Clin Oncol: 28(16):2784-2958.

Hayes, D.F., Thor ,A.D., Dressler, L.G., Zeman, F., Koller,M. Gerstenhauer, M., *et al* . 2013. Ki-67 is prognostic Parameter in Breast cancer Patients: Result of a Large population- based Cohort of a Cancer registry. *Breast cancer res Treat*:139:539-552.

Hernandez-Aya, L.F., Chavez-Macgregor, M., Lei, X., Meric-Bernstam, F., Buchholz, T.A., Hsu, L., Sahin, A.A., Do, K.-A., Valero, V., Hortobagyi, G.N., Gonzalez-Angulo, A.M., 2011. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J. Clin. Oncol. Off. J.Am.Soc.Clin.Oncol.29,2628–2634.

Hon, C.D.J., Singh, B., Sahin, A., Du, G., Wang, J., *et al.* 2016. Breast cancer molecular subtypes: from TNBC to QNBC. Am J cancer Res. 6(9): 1864–1872.

Hoyle, R.2018. Chapter 7. Analysis Technique for Small Population Resesarch. In Nancy Kirkwndall and Jordyn White (Rapporteurs). Improving Health Resesarch on Small Populations. Proceedings of A Workshop. *The National Academies Press*.

Hubalek,M., Czech,T., Müller,H., 2017. Biological Subtypes of Triple-Negative Breast Cancer. Breast Care 2017;12:8–14.

Issa-Nummer, Y., Loibl, S., von Minckwitz, G. and Denkert, C., 2104. 2014. Tumor-infiltrating lymphocytes in breast cancer. A new predictor for responses to therapy. *Oncoloimmunology*,3(January),pp.8-10.

Joensuu, H.,Gligorov, J., 2012. Adjuvant treatments for triple-negative breast cancers. Annals of Oncology 23 (Supplement 6): vi40–vi45, 2012.

- Kaya, V., Yildirim, M., Yazici, G., Gunduz, S., Bozcuk, H., Paydas, S., 2018. Effectiveness of Platinum-Based Treatment for Triple Negative Metastatic Breast Cancer: a Meta-Analysis. *Asian Pac J Cancer Prev*, 19 (5), 1169-1173
- Keegan, T.H., DeRouen, M.C., Press, D.J., Kurian, A.W., Clarke, C.A., 2012. Occurrence of breast cancer subtypes in adolescent and young adult women. *Breast Cancer Res.* 14, R55. <https://doi.org/10.1186/bcr3156>
- Krishnamurti, U., Wetherlit, S.C., Yang, J., *et al.* 2017. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple negative but not estrogen receptor positive breast cancer. *Human Pathology*. S0046-8177(17)30025-
- Laporte, S., Jones, S., Chapelle, C., *et al.* 2009. Consistency of Effect of Docetaxel Containing Adjuvant Chemotherapy in Patient with Early Stage Breast Cancer Independent of Nodal Status : Meta-Analysis of 12 Randomized Clinical Trials. *Cancer; Res* 69 (Suppl 11): Abstr 605.
- Lehman, B.D., Shyr, Y., Pietenpol, J.A., 2011. Identification of human triple negative breast cancer subtypes and preclinical models for selection of targeted therapies. *J Clin Invest.* 121(7);2750-2767.
- Lehman, B.D., Jovanovic, B., Xi Chen., Estrada, M.V., Johnson, K.N., Shyr, Y., *et al.* 2016. Refinement of Triple Negative Breast Cancer Molecular Subtypes: Implication for Neoadjuvant Breast Cancer Molecular Subtypes: Implication for Neoadjuvant Chemotherapy Selection. *Plos One*.
- Lemeshow, S., Hosmer, D.W., Klar, J., and Lwanga, S.K., 1990. Adequacy of Sample Size in health Studies. John Wiley & Sons. New York.
- Leon-Ferre, R.A., Polley, M.-Y., Liu, H., Gilbert, J.A., Cafourek, V., Hillman, D.W., Elkhany, A., Akinhanmi, M., Lilyquist, J., Thomas, A., Negron, V., Boughey, J.C., Liu, M.C., Ingle, J.N., Kalari, K.R., Couch, F.J., Visscher, D.W., Goetz, M.P., 2018. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. *Breast Cancer Res. Treat.* 167, 89–99. <https://doi.org/10.1007/s10549-017-4499-7>.
- Liedke, C., Mazauni, C., Hes, K.R., *et al.* Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. *Journal of Oncology*. 26:1275-1281.
- Lin, N.U., Vanderplas, A., Hughes, M.E., *et al.* 2012. Clinicopathologic Features, Patterns of Recurrence, and Survival among Women with Triple Negative

Breast Cancer in The National Comprehensive Cancer Network.
Cancer;118:5463.

Livasy, C.A., Karaca, G., Nanda, R., *et al.* 2006. Phenotypic Evaluation of the Basal-like Subtype of Invasive-Negative Breast Carcinoma.*Mod Pathol*;19-26.

Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., *et al.* 2014. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. *Annals of Oncology* 25: 1544–1550.

Loi, S., Drubay, D., Adams, S., *et al.* 2019. Tumor- Infiltrating Lymphocytes and Prognosis : A Pooled individual Patient Analysis of Early – Stage Triple-Negative Breast cancers. ASCO. Vol 37. Issue 7: 559-569.

Loibl, S., O’Shaughnessy, J., Untch, M., Sikov, M.W., Rugo, S.H., McKee, D.M., *et al.* 2018. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. *Lancet Oncol* 2018; 19: 497–509.

Lund, M.J., Trivers, K.F., Porters, P.L., *et al.* 2009. Race and Triple Negative threat to Breast Cancer Survival: A population-Based Study in Atlanta, GA. *Breast Cancer Res treat*;113:357-370.

Mahmoed, S.M.A., Paish, E.C., Powe, D.G., Macmillan, R.D., Grainge, M.J., Lee, A.H.S., *et al.* Tumor-Infiltrating CD8 Lymphocytes Predict Clinical Outcome in Breast Cancer. *Journal Of Clinical Oncology*. Volume 9, number 15.

Mao, Y., Qu, Q., Chen, X., Huang, O., Wu, J., Shen, K., 2016. The prognostic value of tumor –infiltrating lymphocyte in breast cancer : systemic review and metanalysis. *PLOS ONE*, 11(4), p.e0152500.

Marme, F., Schneeweiss, A., 2015. Targeted therapies in Triple-Negative Breast cancer. *Breast Care* ;10;159-166.

Martin, M., Segui, M.A., *et al.* 2010. Adjuvant Docetaxel for High-Risk ,Node Negative Breast cancer. *N England J med*;362:2200-2210.

Melichar, B., Studetova, H., Kalabova, H., Vitaskova, D., Cermakova, P., Hornychova, H., *et al.* 2014. Predictive and prognostic significant of tumor-infiltrating lymphocyte in patient with breast cancer treated with neoadjuvant systemic therapy. *Anticancer Research*, 32(3), pp.1115-1125.

Ng, C.H., Pathy, N.B., Taib, N.A., *et al.* 2011. Comparison of Breast Cancer in Indonesia and Malaysia-A clinicopathological Study Between Dharmais

Cancer Center Jakarta and University Malaya Medical Centre, Kuala Lumpur.
Asian Pasific Journal of Cancer Prevention;12:2943-2946.

Ohtani, H., Mori-Shiraishi, K., Nakajima, M., Ueki, H., 2015. Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopatological diagnosis. *PathologyInternational*.65:644-651.

Pogoda, K., Niwin'ska. A., Murawska, M., Pien'kowski, T., 2013. Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. *Med Oncol* (2013) 30:388.

Pistelli, M., Pagliacci, A., Battelli, N., Santinelli, A., Biscotti, T., Ballatore, Z., Berardi, R., Cascinu, S., 2013. Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice. *Anticancer Res.* 33, 2737–2742.

Pruneri, G., Vingiani, A., Bagnardi, V., Rotmensz, N., De Rose, A., Palazzo, A., Colleoni, A.M., Goldhirsch, A., Viale, G., 2016. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. *Ann. Oncol.* 27, 249–256. <https://doi.org/10.1093/annonc/mdv571>.

Rakha, E.A., El-Sayed, M.E., Green, A.R., Lee, A.H.S., Robertson, J.F., Ellis, I.O., 2007. Prognostic markers in triple-negative breast cancer. *Cancer* 109, 25–32. <https://doi.org/10.1002/cncr.22381>.

Rampurwara, M., Wisinski, K.B., O'Regan, R., 2016. Role of the marker prognostic in Triple-Negative Breast cancer. *Clinical Advances in Hematology & Oncology* Volume 14, Issue 3 March.

Rathore, A.S., Kumar, S., Konwar, R., Makker, A., *et al.*, 2014. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast. *Indian J Med Res* 140, September 2014, pp 361-369

Reddy, G.M., Suresh, P.K., Pai, R.R. 2017. Clinicopathological Features of Triple Negative Breast Cancer. *Journal of Clinicopathological and Diagnostic Research*. Jan, Vol-11(1):EC05-EC08.

Rocaa, A., Paradiso, A., Sismondi, P., *et al.* 2011. Benefit from CMF with or without Anthracyclines in Relation to Biologic Profiles in Early Breast Cancer. *J Clin Oncol*;29s: Abstr 1031.

- Ruan, M., Tian, T., Rao, J., *et al.* 2018. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers. *Diagnosis pathology*.13:66.
- Salgado, R., Denkert, C., Campbell, C., Savas, P., Nuciforo, P., Aura, C., *et al.* 2015. Tumor infiltrating lymphocytes and association with pathological complete response and event – free survival in HER2 – positive early stage breast cancer treated with lapatinib and trastuzumab. *JAMA Oncology*, 1(4), pp.448-445. (a)
- Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., *et al.* 2015. The evaluation of tumor - infiltrating lymphocytes (TILs) in breast cancer : recommendations by an International TILs Working Group 2014. *Annals of Oncology*. Volume 26; pp: 260-270. (b).
- Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Dracy, P.K., Smith, M.J., *et al.* 2015. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. *Nat Rev Clin Oncol* ;13(4):228-41.
- Sporikova, Z., Koudelakova, V., Trojanec, R., Hajdich, M., 2018. Genetic Markers in Triple Negative Breast Cancer. *Clinical Breast Cancer*, Vol.18, No. 5, e841-50.
- Stagg, J., Allard, B., 2013. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. *Ther Adv Med Oncol* (5)1.
- Swaim, S., 2008. Triple Negative Breast Cancer: Metastatic Risk and Role of Platinum Agents. *ASCO Clinical Science Symposium*.
- Tečić Vuger, A., 2020. Characteristics and Prognosis of Triple-Negative Breast Cancer Patients: a Croatian Single Institution Retrospective Cohort Study. *Acta Clin. Croat.* 59. <https://doi.org/10.20471/acc.2020.59.01.12>
- Thike, A., Iqbal, J., Cheok, P.Y., Chong, A., Tse, G.M., Tan, B., *et al.* 2010. Triple Negative Breast Cancer : Outcome Correlation with Immunohistochemical Detection of basal Markers. *Am J surg Pathol*;34:956-964.
- Tzikas, A.-K., Nemes, S., Linderholm, B.K., 2020. A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns. *Breast Cancer Res. Treat.* 182, 643–654. <https://doi.org/10.1007/s10549-020-05727-x>.
- Urru, Gallus, Y., Bosetti, C.M.C., Moi, T., Medda, et al., 2018. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. *BMC Cancer*.

- Von, M.G., Schenneeweiss, A., Loibl, S., *et al.* 2014. Neoadjuvant Carboplatin in Patient with Triple-Negative and HER-2-positive Early Breast Cancer (GeparSixto;CBG66): A randomized Phase 2 Trial. *Lancet Oncology*; 15:747-756.
- Wahidin,M., Noviani,R., Hermawan, S., Andriani, V., Ardian,A., Djarir, H., 2012. Population-Based Cancer Registration in Indonesia. *Asian Pacific J Cancer Prev*;13: 1709-1710.
- Widodo, I., Dwianingsih, E.K., Triningsih, E., *et al.* 2014. Clinicopathological Features of Indonesia Breast Cancer with Different Molecular Subtypes. *Asian PAsific Journal Cancer Prevention* ;15:6109-6113.
- YanMao, QingQu, Chen X,OuHuang, Wu J, Shen,K., 2016. The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer : A Systematic Review and Meta-Analysis. PLOSONE|DOI:10.1371/journal.pone.0152500.
- Youlden, D.R., Cramb, S.M., Yip, C.H., Baade, P.D., 2014. Incidence and mortality of female breast cancer in the AsiaPacific region. *Cancer Biol Med* 2014;11:101-115. doi: 10.7497/j.issn.2095-3941.2014.02.005
- Xie, N., Xu, Y., Zhong, Y., Li, J., Yao, H., Qin, T., 2021. Clinicopathological Characteristics and Treatment Strategies of Triple-Negative Breast Cancer Patients With a Survival Longer than 5 Years. *Front. Oncol.* 10, 617593. <https://doi.org/10.3389/fonc.2020.617593>.